* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Julia2
Survey
Document related concepts
Discovery and development of cephalosporins wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Specialty drugs in the United States wikipedia , lookup
Orphan drug wikipedia , lookup
Drug design wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Neuropharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Psychopharmacology wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug discovery wikipedia , lookup
Transcript
Julia Salas CS379a 2-28-06 Aim of the Study • To determine distinguishing features of orally administered drugs – Physical and structural features probed • Druglike: Molecules with desirable pharmacokinetic and pharmacodynamic (PK/PD) properties – Pharmacokinetics: Absorbtion, distribution, metabolism, and elimination (ADME) – Pharmacodynamics: Mechanism of drug action, dosage, mechanism, etc Pharmacodynamics is the study of what a drug does to the body, whereas pharmacokinetics is the study of what the body does to a drug Compounds Surveyed • Three sets of compounds used 1. Known drugs (“Marketed Drugs”): 1,729 • 1193 with oral formulation (good PK/PD) • 536 without oral formulation (poor PK/PD) – Injectable (308), topical (112), and absorbent (116) 2. Clinical candidates: 1,817 3. SAR compounds: 113,937 • Biologically active but not druggable Molecular properties and structural fragments were analyzed Methods: Structural Fragments Chemical Fragments & Molecular Slicer (MS) • Tool to deconstruct molecules into scaffolds and side chain fragments Side Chain Fragment Scaffold Fragment Methods: Physical Properties • • • Molecular weight (MW) Atom count (NATOM) Calculated Log of octanol-water partition coefficient (CLOGP) – Tendency to prefer a non-aqueous or oily environment rather than water – (A measure of lipophilicity) • • • • • • • • Rotatable bonds (ROT) Rings (NRING) Nitrogens and oxygens (ONs) H-bond acceptors (ACC) H-bond donors (DON) Polar surface area (PSA) Surface area (SA) Halogens (halogen) What are the Most Relevant Druglike Properties? Physical Properties: Determining Relevance Correlations observed for the 1,729 marketed drugs: • PSA correlates with ON count, SA correlates with MW, NATOM correlates with MW, DON correlates with NHOH count Relevant: MW, ON, OHNH, ACC, NRING, ROT, HALOGEN, CLOGP Physical Properties: Controlling for (Oral) Drug Approval Date Although the nature and location of drug targets have changed, mean physical properties of the drugs have not Inflammation/Asthma Cardiovascular Central Nervous System Hormones Infectious Disease Metabolic Disease Oral Drugs vs. Nonoral Drugs: Physical Properties • Trends agree with a previously published study Oral Drugs vs. Nonoral Drugs: Physical Properties Property distribution means, medians, and p-values were calculated for the mean values of the oral drugs with the other groups • Injectables are more polar, heavier, and more flexible – Higher mean MW, ON, OHNH, NRING, ROT, H-bond acceptors and lower CLOGP and halogens • Absorbents and Topicals are most similar to oral drugs – Absorbents have (slightly) lower CLOGP and (slightly) higher OHNH counts – Topicals have (slightly) different MW, NRINGS, halogens, CLOGP Common Fragments of Oral vs. Injectable Drugs Side Chains Oral Injectable • Several sidechains found in both groups • The means of the 8 properties are similar Common Fragments of Oral vs. Injectable Drugs Scaffolds Oral Injectable • Injectables: More polar and flexible – ON count, ROT, CLOGP show same trends as whole molecule Conclusions • Differences in physical properties lie in the scaffolds (not side chains) of molecules • Oral drugs have lower MW, balanced CLOGP, and greater rigidity • Knowledge of trends in scaffolds and physical properties may be applied to future searches for oral drug candidates “We cannot accurately classify a particular drug as either oral or injectable on the basis of simple physical property calculations”